Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced feedback from its Type D Meeting with the U.S. Food and Drug Administration (FDA) related to EB613's [daily oral hPTH(1-34), teriparatide, tablets] proposed registrational program for the treatment of postmenopausal women with osteoporosis. Entera submitted a draft phase 3 study protocol and requested the FDA's written responses to two questions.

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced a summary of 2022 corporate achievements and financial results for the year ended December 31, 2022.

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing Entera that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.

Entera Bio Regains Compliance with Nasdaq Listing Requirements

JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that a Type D meeting protocol review has been accepted by the U.S. Food and Drug Administration (FDA) to provide responses by March 30th, 2023. The pivotal, Phase 3 study protocol is entitled “A 24-Month Phase 3, Randomized, Double-Blind, Global Multicenter Study Comparing the Effects of Oral hPTH(1-34) (EBP05[EB613]) Daily Tablets vs. Placebo on Bone Mineral Density (BMD) in Postmenopausal Women with Osteoporosis.” EB613 is the first oral, once daily mini tablet presentation of hPTH (1-34), (teriparatide). EB613 has a well-established mechanism of action, PK and safety profile and met primary (PD/biomarker) and secondary endpoints (BMD) in a placebo controlled, dose ranging Phase 2 study in 161 postmenopausal women with low bone mass and osteoporosis.

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know

Centillion Fund Inc. Ups Stake in Entera Bio (ENTX)

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022.

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates.

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

- Total Hip BMD Established as Primary Endpoint - - Total Hip BMD Established as Primary Endpoint -

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company's lead asset EB613, and its potential impact on the osteoporosis market on Wednesday, September 28, 2022 at 10:00am ET.

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference.

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the details of “A Six-month Phase 2 Study of Oral PTH (EBP05) in Postmenopausal Women with Low Bone Mass – Dose Proportional Absorption and Effect on Lumbar Spine BMD (SUN-591)” poster presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2022, being held from September 9-12th in Austin, Texas. The full text of the abstract will be published to the ASBMR meeting website, and the e-poster will be viewable on Entera's website as of Sunday September 11th as of 1pm CT.

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the formation of its Clinical and Scientific Advisory Board (CSAB), consisting of world class experts in bone diseases, endocrinology, and metabolic disorders. In addition, the Company announced today that it will be presenting new data from its 6-month Oral PTH (EB613) Phase 2 Study in postmenopausal women with low bone mass, or osteoporosis at the 2022 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), which will take place in Austin, Texas from September 9-12, 2022.

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The study's primary.

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company's President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company's Board of Directors, effective June 15, 2022. Dr. Schwartz's resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company.

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

Entera Bio Ltd. (NASDAQ:ENTX ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Spiros Jamas - Chief Executive Officer Miranda Toledano - Chief Business Officer, Chief Financial Officer & Head of Strategy Arthur Santora - Chief Medical Officer Conference Call Participants Kalpit Patel - B.

Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript

BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

Longeveron

TRACON Pharmaceuticals

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Follow the Insiders and Buy the Dip in These 3 Stocks

AstraZeneca

Biogen

Greenwich Lifesciences

GameStop

Roche Holding AG

Riot Blockchain

SPDR S&P Biotech ETF

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript

News for Entera Bio Ltd Stock (ENTX)